ArticleBJU international2026
Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo assess the impact of 5α-reductase inhibitors (5-ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging-Reporting and Data System (PI-RADS) lesions and their influence on the detection of clinically significant prostate cancer (csPCa), with a focus on differences between prostate zones. PATIENTS AND
methodsWe retrospectively reviewed data from 1108 PI-RADS version 2 score 3-5 lesions in 718 patients across a multi-institutional cohort, all of whom underwent magnetic resonance imaging (MRI)-targeted biopsy. A subset of 66 lesions from patients receiving 5-ARI therapy was matched to lesions from untreated patients and independently reviewed by an experienced radiologist in a blinded fashion. Apparent diffusion coefficient (ADC) values were quantified for each lesion and for peripheral and transition zones.
resultsAmong the 1108 lesions, 90 (8%) were in patients on 5-ARI therapy for ≥3 months prior to mpMRI. Multivariable analysis demonstrated that 5-ARI use was associated with significantly reduced odds of detecting csPCa on targeted biopsy (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.18-0.57). Stratified analysis revealed a pronounced reduction in csPCa detection in peripheral zone lesions (OR 0.20, 95% CI 0.05-0.68), but not in transition zone lesions (OR 0.38, 95% CI 0.11-1.18). Blinded radiological review showed higher mean ADC values in peripheral zone lesions among 5-ARI users (869 vs 765 mm
conclusionsTreatment with 5-ARIs is associated with decreased detection of csPCa on MRI-targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false-positive mpMRI findings in patients receiving 5-ARIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.